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ABSTRACT
Objective: The aim of the present study was to analyse the  
relationship between increasing utilization of antidepressants, lithium 
and suicide rate of persons less than 20 years of age in Hungary, 
with particular regard to seasonal patterns.
Methods: Time trend analysis was carried out to determine the  
correlation between antidepressant and lithium prescription patterns 
in Hungarian persons under age of 20 as well as seasonal variations 
within the study period from January 1998 to December 2006.
Results: There was a significant correlation (p=0.03) between the 
eight-fold increase in antidepressant+lithium prescriptions and 
decreasing suicides in young Hungarian people under 20 years of 
age within the study period. Lithium, SSRIs and the group of “other 
antidepressant drugs” rather than nonselective monoamine  
reuptake-inhibitors and monoamine oxidase-A inhibitors were 
responsible for this association. No significant association could be 
drawn from seasonal variation with boys (P=0.964), girls (P=0.140) 
or both genders (P=0.997).
Limitation: Ecological study design
Conclusion: Our findings are in good agreement with large-scale 
ecological studies showing that the beneficial effect of more widely 
used antidepressants at a given point could be appear on the level 
of suicide rate of the general population even among patients under 
the age of 20.
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ABSTRACT 
Objective: The aim of the present study was to analyse the relationship 
between increasing utilization of antidepressants, lithium and suicide rate of 
persons less than 20 years of age in Hungary, with particular regard to seasonal 
patterns. 
Methods: Time trend analysis was carried out to determine the 
correlation between antidepressant and lithium prescription patterns in 
Hungarian persons under age of 20 as well as seasonal variations within the 
study period from January 1998 to December 2006. 
Results: There was a significant correlation (p=0.03) between the eight-
fold increase in antidepressant+lithium prescriptions and decreasing suicides in 
young Hungarian people under 20 years of age within the study period. Lithium, 
SSRIs and the group of "other antidepressant drugs" rather than nonselective 
monoamine reuptake-inhibitors and monoamine oxidase-A inhibitors were 
responsible for this association. No significant association could be drawn from 
seasonal variation with boys (P=0.964), girls (P=0.140) or both genders 
(P=0.997). 
Limitation: Ecological study design 
Conclusion: Our findings are in good agreement with large-scale 
ecological studies showing that the beneficial effect of more widely used 
antidepressants at a given point could be appear on the level of suicide rate of 
the general population even among patients under the age of 20. 
Keywords: Antidepressant agents, Lithium, Suicide, Seasonality, Children and 
adolescents, Food and Drug Administration (FDA) 
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INTRODUCTION 
In spite of the fact that suicidal behaviour is very complex, multicausal human behaviour, 
with several psychiatric, psycho-social, demographic and cultural components up to 90% of 
all suicide related deaths occur in patients with current major psychiatric disorders out of 
them untreated major depression is the most common contributory factor (Bertolote and 
Fleischmann 2002; Rihmer 2007; Hawton and van Heeringen 2009). However, clinical 
studies show that appropriate acute and long-term treatment of major depression (with 
antidepressants and/or with lithium) and bipolar disorders (with mood stabilizers, 
antidepressants and/or antipsychotics) markedly reduces the risk of further suicidal 
behaviour even in this high-risk patient population (Guzzetta et al. 2007; Rihmer and Gonda 
2013). 
Given that suicidality is a well-known symptom and outcome of untreated or inadequaately 
treated depressive illness, the United States Food and Drug Administration Black Box 
warning” (2004) of emergent suicidality in children and adolescents (extended to young 
adults in 2006) based on the antidepressant arm of placebo-controlled randomized trials has 
created understandable concern in clinical practice (FDA 2007; Gibbons et al. 2007). In fact, 
the meta-analysis of Phase II/III randomized controlled clinical trials on antidepressant 
monotherapy in unipolar major depression (from which studies the most severe and acutely 
suicidal patients are excluded, but subthreshold bipolar depressives are included) show a 
nonsignificant increase of suicidal behaviour (but not completed suicides) in patients taking 
antidepressants compared to those who are taking placebo (Mann et al. 2006; FDA, 2007). 
However, the marked antisuicidal effect of antidepressants highly overshadows this rare 
complication and recent findings show that this relatively small increase in suicidality relates 
to depression-worsening potential of antidepressant monotherapy (unprotected by mood 
stabilizers or atypical antipsychotics) in subthreshold bipolar depressives (in clinical trials on 
unipolar depression) and in unrecognized threshold and subthreshold bipolar depressives (in 
real life situation) (Akiskal and Benazzi 2005; Rihmer and Gonda 2011; 2013). Although the 
Black Box Warning was not officially introduced in Hungary, its main message (i.e. the 
possible relationship between antidepressant treatment and suicidality), the explanation of 
this relationship (discussed in the previous sentence) and the possible strategies for 
minimizing the risk of this rare iatrogeny has been continuously discussed in several 
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scientific review papers, book chapters and CME lectures after 2004 in Hungary (Rihmer, 
2005, Rihmer et al, 2007). 
As the consequence of the FDA Black Box Warning, the recently decreased use of 
antidepressants in children and adolescents seen in the USA, The Netherlands (Gibbons et al. 
2007) and Canada (Katz et al. 2008) has been accompained by a concurrent increase in 
suicide rates in that age-groups while in middle-aged and old persons, where the utilization 
of antidepressants increased continuously the suicide rates decreased (Gibbons et al. 2007; 
Katz et al. 2008). The recent paper by Isacsson and Ahlner (2014) analysed individual date 
of all 845 suicides in the 10-19 year age group in Sweden during 1992-2003 and 2004-2010. 
The findings provided further support that the Warning, contrary to its intention, resulted in 
increasing number of young depressives who did not receive antidepressants and the suicide 
mortality in this age group increased by 60 percent for five consecutive years. The individual 
analysis showed that this increase occured among young persons without antidepressant 
treatment. However, analysing the prescription data of 1.1 million adolescents and 6.4 
million adults in the United States between 2000 and 2010, Lu et al. (2014) reported a 31% 
decrease in antidepressant prescription among adolescents after 2004, which was 
accompained by an increase of suicide attempts rather than completed suicides. 
In the last 30 years, the suicide rate of Hungary steadily decreased by more than 50 percent 
while the prescription of antidepressants increased by ten-fold (Rihmer et al. 2013). 
Analyzing the prescription of antidepressants and suicide mortality in the whole population 
of Hungary between 1998 and 2006 there was a significant correlation between the steadily 
increasing antidepressant prescription (113%) and continuous decline in total national 
suicide rate (23%) as well as both in females and males (21% and 23%, respectively). 
Increasing antidepressant utilization was associated with significantly decreased seasonality 
of suicides only among males (Sebestyén et al. 2010). The steep increase in prescription of 
antidepressants and the still high prevalence of suicides in Hungary (Döme et al. 2011; 
Rihmer et al. 2013) provided an opportunity by which the nature of the association between 
antidepressant drug use and suicide could be evaluated separately among persons less than 
20 years old in the same data base used in our previous study (Sebestyén et al. 2010). Based 
on the evidence that pharmacotherapy of depression is highly beneficial for suicide mortality 
(Rihmer and Gonda 2013) we worked with the hypothesis that antidepressants by treating 
In
t J
 P
sy
ch
 C
lin
 P
ra
ct
 D
ow
nl
oa
de
d 
fro
m
 in
fo
rm
ah
ea
lth
ca
re
.c
om
 b
y 
N
yu
 M
ed
ic
al
 C
en
te
r o
n 
06
/1
1/
15
Fo
r p
er
so
na
l u
se
 o
nl
y.
depression, the major risk factor for suicide, would result in a reduction in suicide mortality 
in young persons under age of 20 too. Because seasonality of suicides is mainly the 
consequence of the seasonal incidence of depression–related suicides, suggesting that 
decreasing seasonality of suicides might be a marker of lowering rate of depressive suicides 
in the population (Rihmer et al. 1998, Mergl et al. 2010; Sebestyén et al. 2010), we have 
postulated that this reduction would be most visible in the months when suicide peaks 
resulting in a decreasing seasonal variation of suicide death rates. The antisuicidal effect of 
lithium is well-known (Guzzetta et al. 2007; Rihmer and Gonda 2013) but according to our 
best knowledge there is no study yet on the possible association between the amount of 
lithium prescribed at the level of population and suicide rates in Hungary. 
Shortly, our primary aim was to check the adequacy of the concern of the FDA about the 
safety of antidepressants among children and adolescents with investigating the association 
between the amount of antidepressants (and lithium) prescribed and suicide rate in people 
under 20 years of age in a country where Black Box Warning for antidepressants (FDA, 
2007) has not been applied. 
MATERIALS AND METHODS 
Suicide Data 
Mortality data was sourced from the Hungarian Central Statistical Office 
describing deaths due to suicides in Hungary from January 1 1998 to 
December 31 2006. Suicide rates were classified based on age (children and 
adolescents less than 20 years categorized into 5 year groups) as well as 
gender, each classification having its calculations for monthly and annual 
number of suicide related deaths. The suicide rates obtained were 
standardized for age and gender using the Hungarian population at the 
beginning of 2008 as standard. The indicator used was standardized death 
rates (SDR) calculated as the number of suicides/100,000 inhabitants/year. 
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On the other hand, the number of suicide deaths and the average daily 
number of deaths were determined for each investigated bimonthly period. 
The average and the standard deviation of these average daily case numbers 
were estimated for each year of our study as well. The variation coefficient 
for each year was calculated as the standard deviation / mean of daily number 
of suicide deaths for all of studied years. This indicator was used in 
describing the seasonality. 
Antidepressant and lithium prescription data 
Data on antidepressant and lithium prescription was obtained from the 
Hungarian National Health Insurance Fund (NHIF). This also covered the 
whole country as the suicide data collected and spanned 9 years (January 1 
1998 to December 31 2006). Health insurance being mandatory for every 
citizen living in Hungary suggests that we can safely assume that 
antidepressant prescription data from the NHIF (which has the personal 
identification and prescriptions of all insured persons) gives a true 
representation of the national drug prescription. 
The psychotropic drugs (with ATC codes) for which data was collected 
included the following groups: lithium (N05AN01), antidepressants: 
nonselective monoamine reuptake inhibitors (N06AA), selective serotonin 
reuptake inhibitors (SSRIs, N06AB), monoamine oxidase-A inhibitors 
(RIMA, N06AG), all other drugs used in the treatment of depression 
(N06AX). Our database contained the amount and ATC codes of 
antidepressant drugs prescribed for teenagers less than 20 years old by 
gender, and by year studied, respectively. The drug prescription was 
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summarized for the above mentioned ATC categories and for all 
antidepressants and lithium applying WHO defined daily doses. The 
indicator describing lithium and antidepressant drug use was the Daily 
Defined Dose (DDD) for 1,000 inhabitants per day in each year studied. 
Statistical Analyses 
Regression coefficients from Autoregressive Integrated Moving Average 
(ARIMA) method were used to describe association between time trend of 
standardized suicide death rates and prescribed doses of antidepressants. 
ARIMA was also applied to investigate the relationship between the trend of 
antidepressant drug prescription and the seasonality index in suicide rates 
(Box et al., 1994). All the investigated variables have been checked by 
Kolmogorov-Smirnov test for normality before ARIMA application. 
Analyses were carried out using SPSS 17.0 software. For more detailed 
description of data collection and statistical analysis see also Sebestyén et al., 
2010. 
RESULTS 
There were 479 registered suicide deaths (375 boys and 104 girls) in the 
studied population between 1998 and 2006. The descriptive data are outlined 
in Table 1, which highlights continuously increasing amounts of prescription 
of lithium and individual antidepressant groups. Besides nonselective 
monoamine reuptake inhibitors, all other groups of lithium and 
antidepressants had remarkable increase in prescription rates. The combined 
increase in antidepressant + lithium consumption between 1998 and 2006 
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was approximately eightfold while suicide rate among persons under 20 
declined by 11 percent. 
There was a general inverse association between time-trends of 
antidepressants + lithium usage and suicide by ARIMA (b= -0.132; p= 
0.030). Significant association was observed between prescription of lithium 
(b= -18.223; p= 0.032), SSRIs (b= -0.164; p= 0.026), other antidepressants 
(b= -0.873; p=0.035) and teenage suicide rate, suggesting that they might 
play role in the reduction of suicide related deaths. Nonselective monoamine 
reuptake inhibitors’ as well as RIMAs' influence was not significant in this 
analysis. (Table 2). 
Figure 1 presents the seasonal variations of suicide among teenagers less 
than 20 year old in Hungary. The boys have a higher occurrence of suicides 
than the girls (approximately 3 times the value for girls), with suicides 
tending to peak in the summer months. The seasonality index was calculated 
as the within year variation coefficient for teenage boys, girls and also as a 
total estimate for both genders. There was very little change in seasonality 
for either gender from 1998 till 2006, the final index been almost the same as 
the start of index. This implies that the standard deviation within each year 
(corresponding to the fluctuation between peak and low seasons did not 
change much within our study period). Antidepressant consumption on the 
other hand as stated earlier showed remarkable increase throughout the 
period of the study (Table 3). 
DISCUSSION 
Since the “Black Box” warning was not considered in Hungary the use of antidepressants 
continued to increase, but this was not followed by an increase in youth suicide that could 
have validated the Black Box warning. Our descriptive results demonstrate the moderate 
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reducing trend of suicides and the remarkable increase in antidepressant drug prescription in 
Hungary amongst persons under age of 20, which trend is similar to our previously 
published finding on the whole population of Hungary during the same time-period 
(Sebestyén et al. 2010). This inverse association has proved to be significant, suggesting that 
antidepressant drugs treatment was a contributing factor to the reduction in suicide rates 
among young patients in Hungary. Lithium, SSRIs and the group of other antidepressant 
drugs rather than nonselective monoamine reuptake-inhibitors and RIMA antidepressants 
were responsible for this association. The anti-suicidal effect of lithium – even in unipolar 
major depression – is well known (Guzzetta et al. 2007, Rihmer and Gonda 2013). It should 
be noted that in Hungary lithium is frequently used in combination with other 
antidepressants, but in our present study we could not identified the subpopulation of young 
patients who receive this combination. However, it can be assumed that the increased 
coverage of and treatment of depression reduced the complications of depression, foremost 
of which the most serious and most visible is suicide. Although antidepressants are less 
frequently effective in children and adolescents than in older persons (Walsh et al. 2002; 
Bridge et al. 2007), if appropriately used, they treat depression successfully and 
consequently reduce the risk of suicidal behaviour. The significant role of antidepressants 
and lithium in reducing suicide mortality of persons under age of 20 is very likely, because 
several psycho-social and medical risk factors of suicide (like unemployment, 
divorce/separation, long-lasting alcohol consumption and severe/multiple somatic disorders) 
(Rihmer 2007; Hawton and van Heeringen 2009) rarely occur in this age group (as a whole). 
Accordingly, interventions aiming suicide risk reduction among teenagers should focus on 
other factors such as depression. Our present findings are in good agreement with large-scale 
ecological studies showing that the beneficial effect of more widely used antidepressants at a 
given point could be appear on the level of general population (Ludwig et al. 2009; Gusmao 
et al. 2013). Our results also provide indirect support of the studies of Gibbons et al. (2007), 
Katz et al. (2008) and Isacsson and Ahlner (2014) reporting that the decreased use of 
antidepressants in children and adolescents after the FDA Black Box Warning has been 
accompained by a concurrent increase in suicide rates in that age-groups while in middle-
aged and old persons, where the utilization of antidepressants increased continuously the 
suicide rates decreased. 
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Considering the previously published findings on increased antidepressant utilization and 
decreasing seasonality of suicidal behaviour (Rihmer et al. 1998; Mergl et al. 2010; 
Sebestyén et al. 2010) we would have expected that an 8-fold increase in antidepressant drug 
and lithium prescription should be associated with a corresponding decrease in seasonality 
index if antidepressant drug use is significantly associated with suicide, but our study 
showed no such correlation since the seasonality index remained almost unchanged. 
Increasing antidepressant drug consumption among teenage and young adult Hungarian boys 
and girls – maybe due to small numbers – seems to have no association with decreasing 
seasonal variations of suicide related deaths. 
Our study has some limitations. Firstly, this is an ecological study, thus it cannot infer 
causality at an individual level (Robinson 1950). Secondly, we were not able to check 
whether all the prescribed psychotropic agents were taken by the patients. Thirdly, the rate of 
patients receiving any antidepressant plus lithium is unknown. The fourth possible limitation 
of our study is due to that antidepressants are also prescribed for some other disorders (e.g. 
different kinds of anxiety disorders) than major depression; accordingly it is probable that a 
small part of antidepressant utilization was occurred among subjects with other diagnosis 
than depression. However, this bias is negligible if we analyze the long-term trend of change 
their utilization. 
Key points 
 There  is  a  lively  debate  on  the  supposed  suicide‐provoking  effects  of 
antidepressants among childen and adolescents. 
 Some  authors  suggested  that  the  within‐year  seasonal  distribution  of 
suicide  cases  is  mainly  the  consequence  of  the  seasonal  incidence  of 
depression‐related  suicides,  suggesting  that  decreasing  seasonality  of 
suicides might be a marker of  lowering  rate of depressive  suicides  in  the 
population. 
 In  our  ecological  study  we  aimed  to  discern  the  correlation  between 
antidepressant and  lithium prescription and suicide  rate  in the Hungarian 
population aged under 20 years. We also investigated the supposed effect 
on  antidepressant  utilization  on  seasonality  of  suicides  in  the  same 
population. 
 We  found  a  significant  correlation  between  the  increase  in 
antidepressant+lithium  prescriptions  and  decreasing  suicides  within  the 
study  period  (1998‐2006).  On  the  other  hand,  we  were  not  able  to 
demonstrate  that  increasing  antidepressant  drug  consumption would  be 
associated with decreasing seasonal variations of suicide related deaths. 
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Table Legends 
Table 1. Annual prescription of lithium and antidepressants (DDD/1000 
persons/day) with corresponding standardized suicide deaths rates (per 
100.000) for young persons (< 20 years old) in Hungary between 1998 and 
2006. 
Year Lithium 
Non-
selective 
monoami
ne 
reuptake 
inhibitors 
Selective 
serotonin 
reuptake 
inhibitors 
(SSRIs) 
RIMA 
antidep
ressant 
Other 
anti-
depressant
s 
Anti-
depressan
ts + 
lithium 
together 
Suicid
e rate 
1998 0.007 0.211 0.261 0.018 0.008 0.498 2.368 
1999 0.008 0.245 0.512 0.040 0.022 0.818 2.966 
2000 0.009 0.212 0.720 0.058 0.037 1.027 2.544 
2001 0.013 0.238 1.079 0.081 0.071 1.469 2.275 
2002 0.018 0.263 1.438 0.117 0.168 1.986 2.735 
2003 0.020 0.239 1.956 0.150 0.282 2.627 2.301 
2004 0.025 0.224 2.206 0.140 0.337 2.907 2.709 
2005 0.026 0.252 2.770 0.160 0.372 3.553 2.121 
2006 0.034 0.208 3.240 0.143 0.562 4.154 2.099 
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Table 2. Association between lithium's and antidepressants’ prescriptions 
(DDD/1000persons/day) and standardized suicide deaths rates (per 100.000) 
among Hungarian children and adolescents (< 20 years old) in 1998-2006 by 
ARIMA. 
 Lithium 
Non-selective 
monoamine 
reuptake 
inhibitors 
Selective 
serotonin 
reuptake 
inhibitors 
(SSRIs) 
RIMA 
antidepressant 
Other 
antidepressants 
Antidepressants 
+ lithium 
together 
b -18.223 3.986 -0.164 -2.533 -0.873 -0.132 
p 0.032 0.539 0.026 0.122 0.035 0.030 
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Table 3. Antidepressants’ + lithium's prescription (DDD/1000 persons/day) 
and seasonality index for bimonthly suicide rates among young Hungarian 
boys and girls (< 20 years old) between 1998 and 2006. 
Boys Girls Total 
Yea
r 
Anti-
depressants
’ + lithiums' 
prescription 
Seasonality 
index 
Anti-
depressants
’ + lithiums' 
prescription 
Seasonality 
index 
Anti-
depressants
’ + lithiums' 
prescription 
Seasonality 
index 
199
8 0.19 0.414 0.17 0.977 0.18 0.410 
199
9 0.30 0.450 0.30 0.865 0.30 0.434 
200
0 0.36 0.562 0.39 0.831 0.37 0.441 
200
1 0.51 0.698 0.57 0.92 0.54 0.685 
200
2 0.65 0.521 0.80 1.085 0.72 0.451 
200
3 0.85 0.578 1.08 0.853 0.96 0.424 
200
4 0.93 0.484 1.20 0.739 1.06 0.484 
200
5 1.11 0.517 1.50 1.431 1.30 0.537 
200
6 1.29 0.447 1.76 1.005 1.52 0.403 
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Figure Legend 
Figure 1. Within year distribution of 479 suicide deaths (375 boys and 104 
girls) among Hungarian adolescents (< 20 years old) for the period of 1998 to 
2006 by bimonthly number of cases. 
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